ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,509.01
0.62%
US Tech 100
19,460.00
0.95%
Dow Jones
39,331.85
0.41%
Brent Oil
86.445
0.00%
Bitcoin
61,437.95
-0.95%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Carisma Therapeutics Inc (CARM) Quote

Carisma Therapeutics Inc

Carisma Therapeutics Inc (CARM)

Carmanah Minerals Corp
Carrefour Property Development
1.44
-0.23
(-13.77%)
Closed July 02 4:00PM
Delayed by 15 minutes
1.44
0.00
(0.00%)
After Hours: 7:50PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
1.44
Bid
1.37
Ask
1.44
Volume
1,481,546
1.44 Day's Range 1.66
0.99 52 Week Range 9.7662
Market Cap
60.237M
Previous Close
1.67
Open
1.59
Last Trade
2
@
1.42
Last Trade Time
Financial Volume
$ 2,267,012
VWAP
1.5302
Average Volume (3m)
319,180
Shares Outstanding
41,542,744
Dividend Yield
-
PE Ratio
-0.69
Earnings Per Share (EPS)
-2.09
Revenue
14.92M
Net Profit
-86.88M

About Carisma Therapeutics Inc

Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company¿s lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company¿s second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.carismatx.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Carisma Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CARM. The last closing price for Carisma Therapeutics was $1.67. Over the last year, Carisma Therapeutics shares have traded in a share price range of $ 0.99 to $ 9.7662.

Carisma Therapeutics currently has 41,542,744 shares outstanding. The market capitalization of Carisma Therapeutics is $60.24 million. Carisma Therapeutics has a price to earnings ratio (PE ratio) of -0.69.

CARM Latest News

More News

CARMILA: Information Concerning the Total Number of Voting Rights and Share

provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des marchés financiers (General regulation of...

11 hours ago
Business Wire

CARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers

Regulatory News: CARMILA (Paris:CARM) : Date Nombre d’actions composant le capital social Nombre réel de droits de vote (déduction faite des actions auto- détenues) Nombre théorique de droits de...

11 hours ago
Business Wire

Carmila: Closing of the Acquisition of Galimmo SCA

Carmila announces the closing of the acquisition of 93% of the share capital of Galimmo SCA Galimmo’s portfolio of 52 assets, mainly located in the North-East of France, was valued at 675...

July 01 2024
Business Wire

Carisma Therapeutics Announces Changes to its Board of Directors

Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire PHILADELPHIA, July 1, 2024 Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and...

July 01 2024
PR Newswire (US)

Carmila : Participation dans Galimmo SCA potentiellement portée à 99,9%

Regulatory News: Le 28 juin 2024, Carmila (Paris:CARM) a consenti à une entité gérée par Primonial REIM France une promesse unilatérale d’achat portant sur l’intégralité de la participation...

July 01 2024
Business Wire

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna PR Newswire PHILADELPHIA, June 27, 2024...

June 27 2024
PR Newswire (US)

Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum

Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum PR Newswire PHILADELPHIA, June 25, 2024 PHILADELPHIA, June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq:...

June 25 2024
PR Newswire (US)

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors PR Newswire PHILADELPHIA, June 25, 2024 Fast Track designation highlights...

June 25 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

June 18 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 14 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2925.21739130431.151.71.0422296551.41938802CS
40.1410.76923076921.31.70.996548501.35470544CS
12-0.59-29.06403940892.032.04970.993191801.42591319CS
26-1.48-50.68493150682.923.060.992307841.7654525CS
52-7.45-83.80202474698.899.76620.992255603.1725883CS
156-4.35-75.12953367885.799.76620.992372114.0126996CS
260-4.35-75.12953367885.799.76620.992372114.0126996CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RDZNRoadzen Inc
$ 2.95
(82.10%)
107.99M
SYTSYLA Technologies Company Ltd
$ 3.05
(59.69%)
6.19M
VSVersus Systems Inc
$ 1.90
(43.94%)
58.92M
VIVKVivakor Inc
$ 3.41
(36.95%)
727.57k
MEDSTRxADE HEALTH Inc
$ 18.585
(30.70%)
397.65k
MAXNMaxeon Solar Technologies Ltd
$ 0.18
(-67.20%)
173.82M
RNACCartesian Therapeutics Inc
$ 15.7715
(-35.02%)
1.45M
EFTReFFECTOR Therapeutics Inc
$ 0.18
(-32.56%)
1.63M
DTSSDatasea Inc
$ 3.43
(-30.57%)
1.15M
ARDXArdelyx Inc
$ 5.29
(-30.12%)
22.67M
NVDANVIDIA Corporation
$ 122.67
(-1.31%)
220.35M
TSLATesla Inc
$ 231.26
(10.20%)
205.02M
MAXNMaxeon Solar Technologies Ltd
$ 0.18
(-67.20%)
173.82M
SQQQProShares UltraPro Short QQQ
$ 7.88
(-2.96%)
114.53M
RDZNRoadzen Inc
$ 2.95
(82.10%)
107.99M

CARM Discussion

View Posts
PonkenPlonken PonkenPlonken 1 day ago
pretty strong
nice tech$
👍️0
glenn1919 glenn1919 5 days ago
CARM.......................https://stockcharts.com/h-sc/ui?s=CARM&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 5 days ago
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
👍️0
Termite7 Termite7 1 month ago
Could it be CARM under $0.30 ....???.......Thanks!!!
👍️0
axelvento axelvento 2 months ago
$1.46 bouncer
👍️0
PonkenPlonken PonkenPlonken 2 months ago
https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-023-00537-x
MRNA provides the tech, 3bln + in biobucks and has not so distant private relative with TOP tier c suite.
👍️0
Monksdream Monksdream 3 months ago
CARM under $3
👍️0
mrplmer mrplmer 6 months ago
Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
👍️0
mrplmer mrplmer 6 months ago
Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
👍️0
81vette 81vette 7 months ago
1st higher high today and bid growing now,I got some 2.64,will see if dump continues or not
👍️0
81vette 81vette 7 months ago
Yea,distribution only so far today,I am watching for accumulation to start after this dumpathon,short interest went up 300% today also, 100k now,no sign of institutional buying yet,they currently hold 19%
👍️0
stock1ace1 stock1ace1 7 months ago
Red on news .. we no what that means lol
👍️0
81vette 81vette 7 months ago
Deal with Moderna for cancer cures,institutional might buy now lol,went up last time on this news,analysts target $9.50,short 2.45M,not optionable is good,gap filled down now,52 week low 2 weeks ago
👍️0

Your Recent History

NASDAQ
CARM
Carisma Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved